Product Code: TRL474K
Targeted Oncology Therapies
The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of lung cancers. This report examines two dozen therapeutic drugs targeting lung cancer, and the biomarkers they utilize.
What You Will Learn:
- What is the market share of approved therapeutics?
- What is the global supply picture for targeted therapeutics?
- Who are the market leaders, by Indication? by Product?
- What is the therapeutic coverage across all oncology indications? What are the product opportunities?
- What are the established products in this space? by target, indication, API class, revenue?
- What is the competitive picture for the major Oncology market segments?
- Who are the leading competitors in the field of next-generation therapeutics?
Numerous Charts, Tables & Visualizations
Clear & Concise Market Segment Data
Table of Contents
- Summary of Contents
- Executive Summary
- The Recombinant Drug Ecosystem
- Biological Drug Activity by Region
- Biological Oncology Market Leaders
- Oncology mAbs: Competitive Considerations
- mAbs and Targeted Oncology Therapeutics
- Historical Growth of Biologicals
- Leading Biological Drug Companies - Activity by Drug & Segment
- FDA Approved mAbs Indicated for Lung Cancers
- FDA Approved TKIs Indicated for Lung Cancers
- Key Therapeutic Targets
- ALK Gene
- ROS-1 Gene
- The Addressable Market
- Drugs in Development
- Leading Lung Cancer Supplier Assessments